

## Appendix

**Table 1A.** Baseline Characteristics of Patients Initiating Exenatide or Non-Exenatide (TZD, basal insulin, or DPP4I) Therapies, % Unless Otherwise Noted

	Exenatide (n = 1345)	Non-Exenatide (n = 1345)	Non-Exenatide by Individual Therapy		
			TZD (n = 1061)	Basal Insulin (n = 224)	DPP4I (n = 60)
<b>Demographics</b>					
Age (years)	47.90	48.03	48.12	48.03	46.33
Sex, female	78.51	79.48	78.98	79.46	88.33
<b>Race</b>					
White	68.32	68.48	70.97	57.14 <sup>a</sup>	66.67
Black	20.30	20.22	18.10	31.25 <sup>a</sup>	16.67
Hispanic	0.97	1.04	1.13	0.89	0
Other	10.41	10.26	9.80	10.71	16.67
<b>Comorbidities</b>					
CCI (score)	1.97	1.96	1.86 <sup>a</sup>	2.39 <sup>a</sup>	2.02
Hypertension	48.62	52.04	49.67	58.48 <sup>a</sup>	70.00 <sup>a</sup>
Hyperlipidemia	32.79	33.90	33.27	30.80	56.67 <sup>a</sup>
COPD	22.75	23.36	22.62	23.21	36.67 <sup>a</sup>
CHF	6.62	6.10	5.09 <sup>a</sup>	10.27 <sup>a</sup>	8.33
Stroke	2.38	2.38	2.07	3.13	5.00
ESRD	0.30	0.15	0.19	0	0
<b>Prior therapies</b>					
SU	57.84	57.92	57.68	61.16	50.00
Metformin	58.00	58.29	59.28	54.46	55.00
Both SU and metformin	34.20	33.38	34.12	30.80	30.00
Physician was ever a prescriber of exenatide	100	65.58	63.52 <sup>a</sup>	70.54 <sup>a</sup>	83.33 <sup>a</sup>
CCI indicates Charlson Comorbidity Index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DPP4I, dipeptidyl peptidase-4-inhibitor; ESRD, end-stage renal disease; SU, sulfonylurea; TZD, thiazolidinedione.					
<sup>a</sup> Indicates value is statistically different ( $P < .05$ ) compared with exenatide group.					


**Table 2A.** Unadjusted Spending Outcomes in the Year Following Initiation of Exenatide or Non-Exenatide Therapies (TZD, basal insulin, or DPP4I)

Spending Outcomes	Exenatide (n = 1345)	Non-Exenatide (n = 1345)	Non-Exenatide by Individual Therapy		
			TZD (n = 1061)	Basal Insulin (n = 224)	DPP4I (n = 60)
Inpatient	\$1945.35	\$4241.61 <sup>a</sup>	\$3236.85 <sup>a</sup>	\$9870.88 <sup>a</sup>	\$993.29
Outpatient	\$5379.72	\$6826.19 <sup>a</sup>	\$6896.64 <sup>a</sup>	\$6764.65 <sup>a</sup>	\$5810.10
Prescription	\$4504.87	\$5877.63 <sup>a</sup>	\$5856.31 <sup>a</sup>	\$6196.32 <sup>a</sup>	\$5062.91
<b>Total</b>	<b>\$11,829.94</b>	<b>\$16,945.43<sup>a</sup></b>	<b>\$15,989.80<sup>a</sup></b>	<b>\$22,831.85<sup>a</sup></b>	<b>\$11,868.31</b>

DPP4I indicates dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione.


<sup>a</sup>Indicates value is statistically different ( $P < .05$ ) compared with exenatide group value.

■ **Figure 1A.** Regression-Adjusted Spending Outcomes in Patients of Physicians Who Prescribe Exenatide Compared With Patients Whose Physicians Never Prescribed Exenatide



Values of adjusted means are shown in the center of each bar. Standard error bars are shown. *P* values are in comparison to the exenatide group. *N* = 2656 patients (1328 patients of exenatide prescribers and 1328 patients of exenatide non-prescribers). Controls for patient characteristics: age, sex, race, comorbidities, prior therapy, and year of treatment initiation.

**Figure 2A.** Regression-Adjusted Spending Outcomes in Patients Receiving Exenatide, a TZD, Basal Insulin, or a DPP4I



DPP4I indicates dipeptidyl peptidase-4-inhibitor; TZD, thiazolidinedione. Values of adjusted means are shown in the center of each bar. Standard error bars are shown. *P* values are in comparison to the exenatide group. *N* = 2656 patients (1328 receiving exenatide, 1046 a TZD, 227 receiving basal insulin, and 55 a DPP4I). Controls for patient characteristics: age, sex, race, comorbidities, prior therapy, and year of treatment initiation.